Solvay

About: Solvay is a company organization based out in Brussels, Belgium. It is known for research contribution in the topics: Catalysis & Polymer. The organization has 6083 authors who have published 7004 publications receiving 105745 citations.

Manufacture of dicarboxylic acid anhydrides

Abstract: This invention relates to the manufacture of dicarboxylic acid anhydrides and is particularly concerned with the manufacture of phthalic anhydride and maleic anhydride by catalytic vapor phase oxidation by means of new and improved catalytic materials. In the commercial production of the dicarboxylic...

Glycerol-based product, process for obtaining same and use thereof in the manufacture of dichloropropanol

Abstract: The invention relates to a glycerol-based product comprising at least one nitrogen-containing compound and of which the total content of nitrogen-containing compound expressed as elemental nitrogen (N) is less than or equal to 1 g of nitrogen (N)/kg of product, to a process for obtaining glycerol, and to its use in the manufacture of dichloropropanol and of derived products such as epichlorohydrin and products derived from epichlorohydrin.

Retinoic Acid Enhances Fibrinolytic Activity In-Vivo by Enhancing Tissue Type Plasminogen Activator (t-PA) Activity and Inhibits Venous Thrombosis

Abstract: We studied the profibrinolytic effect and the anti-thrombotic potential of retinoic acid in-vivo. Male Wistar rats were treated with retinoic acid either acutely or twice daily for a period of 5 consecutive days in a dose range of 0.01 to 3.0 mg/kg. Fibrinolytic activity was measured ex-vivo using the diluted blood clot lysis test and net t-PA activity in tissue extracts was measured in a spectrophotometric rate assay. Clot lysis was dose dependently increased by retinoic acid up to about 170% (relative to vehicle treated rats) at a dose of 3 mg/kg. No tachyphylaxis could be detected. Ex-vivo measured fibrinolytic activity after single administration of 1 mg/kg of retinoic acid peaked at 3 h after ingestion. Even after 18 h a significantly higher clot lysis rate was measured. Lysis of blood clots from vehicle and retinoic acid treated rats could be completely blocked by addition of tranexamic acid or antibodies against rat t-PA before clot formation. t-PA activity in plasma was slightly increased after retinoic acid treatment; no effects were measured on plasma PAI-1, u-PA, plasminogen, and α2-antiplasmin levels. t-PA activity in lung and kidney was marginally enhanced by retinoic acid but in heart and aortic tissue extracts t-PA activity was increased by about 50%. We confirmed this potential anti-thrombotic property in an in-vivo venous thrombosis model. A reduced clot size was observed after retinoic acid administration (35% reduction at a dose of 1 mg/kg). We could not detect any effect on ex-vivo measured platelet aggregation, bleeding time, prothrombin time, thrombin time, partial thromboplastin time or plasma fibrinogen level, indicating that there were no effects on platelet aggregation or blood coagulation. We conclude that retinoic acid enhanced fibrinolytic activity in-vivo by selectively enhancing t-PA activity and that retinoic acid is a potential anti-thrombotic agent in-vivo.

Mixtures of polar polymers and dedoped conductive polymers, processes for obtaining these mixtures and use of these mixtures to produce electronic, optoelectrical, electrical and electromechanical devices

Abstract: A polymer mixture, including at least one conductive polymer which has been dedoped to provide at least one dedoped conductive polymer; and at least one polar polymer. The polymer mixture has outstanding dielectric properties so that the polymer mixture is useful for producing electronic, optoelectrical, electrical and electromechanical devices.